三生制药2023 中期报告

2023 23562636383940424446 rhEPOrhTPOIQVIA1264.6%rhEPOrhEPO42.9%CPA70.3%TNFαTNFα23.7%CDMO 302530146101013RABRVO52 2416pegsiticase1PD-1 5,3118,700 Cricket Square, Hutchins DrivePO Box 2681Grand Cayman, KY1-1111Cayman Islands 13 3485 Conyers Trust Company (Cayman) LimitedCricket Square, Hutchins DrivePO Box 2681Grand Cayman, KY1-1111Cayman Islands 183171712–1716 97927 97914 77334 1530 www.3sbio.com Conyers Dill & Pearman8129 77 *# 689.322.3%3,783.8 636.424.8%3,201.682.9%84.6% 13.71.4%980.61199.320.1%1,191.5 EBITDA37.52.9%1,330.5EBITDA2228.417.7%1,518.1 * 3 III III78%(TPO) ®NDA ®OD2.5μgNDAHJ20230091κ2023LP00912 管 理 層 討 論 及 分 析 rhTPOCITITPCITITP CITITP(CSCO)CTIT20224rhTPOI20205rhTPOITPITPITP20196rhTPOCITrhTPO 1IL23CITITP25%35%33.1%64.6%ITPNDAIII CKDCIArhEPOrhEPO10,000IU123424 IITNFαRAASRAASTNFα18CMATNFαRATNFαRATNFαEULAR2022(GRAPPA)20217TNFα23.7%123301SNDA16 管 理 層 討 論 及 分 析 FcHER2HER2HER2(CSCO)2022HER2I20222023(ASCO)8HER21,300 OTCAGAFDA123AGA20225%(FAGA) 70.3%35.3%64%123ROGAINE® 2.52–3% ® TRK-820Remitch®NDATRK-820 DOPPS (Dialysis Outcomes and Practice Patterns Study)39%19% 管 理 層 討 論 及 分 析 TRK-820κ(kappa)-opioidTRK-820TRK-8205μg2.5μgTRK-820 TRK-820HBV9,000HCV1,00070017,300–31,0006,2004620%–70%20%–60%20%–50%5.1%–58.4%HCV8%–36.2%HBV57.8%Remitch TRK-820 CDMO CDMOSirton Pharmaceuticals S.p.ASirton500GMPCDMO1107.6 CDMOmRNA(CMC)10L10KL2CDMO(PIC/S)SirtonGMP CDMOCDMO95160 管 理 層 討 論 及 分 析 Winlevi® CosmoPharmaceuticals N.V.Cosmo1%WS204INDCosmoCassiopeaWinlevi® 201995%3%–7%11025 WS2041%CosmoAR12Winlevi®FDA40FDA(MOA)1%CosmoWinlevi®15,000670,000WS204AR SSS06NuPIAOrhEPO608IL-17A601ABRVOVEGF613IL-1ßRD-01rhEPO611IL4Rα610IL-5SSS07RATNFαpegsiticaseHIF-117SSS17HIF(Winlevi) 600 302530146101013RABRVO52 (1)*(2)BE(3)ANDA 管 理 層 討 論 及 分 析 研發管線 (MN709)MN709ROGAINE®MN709ROGAINE®NDA (TRK820)NDAIII (TPO)rhTPOITPNDAIII Pegsiticase (SSS11)Swedish Orphan Biovitrum ABSOBISobiSEL-212SEL-212pegsiticasepegadricaseSSS11b NuPIAO (EPO, SSS06)SSS06CSR(Clinical Study Reports) IL-17A(608)608608 601ABRVO180 IL-1ß(613)613(AG)INDIIIIICDECDE IL4Rα(611)aADIIADIND611(CRSwNP)INDIICOPD)IIIND IL5(610)610Ib32IIII HIF-117 (SSS17)SSS17SSS17HIFHIFαSSS17rhEPO 管 理 層 討 論 及 分 析 IND PD1VEGF(707)aa707CLF2PD1VEGFFDA NGF(SSS40)(NGF)a IL-33(621)COPDINDCOPDIND 2,7041,1441,8892,7006,000 2022 (WS204) ®608IL-17AIII ® 管 理 層 討 論 及 分 析 3,783.83,094.5689.322.3% 2,019.11,575.4443.728.2%53.4% 463.2533.169.913.1%365.9406.840.910.1%97.4126.328.922.9%12.2% 507.5374.3133.235.6%495.5366.2129.335.3%13.4% 303.725.0% CDMO94.955.339.671.6%CDMO (1)(2)417.0338.678.423.2%108.667.740.960.4%150.6118.332.327.3% 529.3582.315.4% 3,201.62,565.2636.424.8%82.9%84.6% -7.2349.0356.2102.1% 管 理 層 討 論 及 分 析 1,374.81,150.3224.519.5%37.2%36.3% 214.4198.116.38.2%5.7%6.4% 306.6294.312.34.2%8.1%9.5% 5.1105.1100.095.1% 88.936.552.4143.6%65.57.957.6729.1% 207.6164.043.626.6%17.4%14.7% EBITDA 980.6966.913.71.4%(a)(b)(c)(d)(e)1,191.5992.2199.320.1% EBITDA1,330.51,293.037.52.9%EBITDAEBITDA(a)(b)(c)(d)(e)EBITDA1,518.11,289.7228.417.7% 管 理 層 討 論 及 分 析 0.400.392.6% 1,184.51,027.6156.915.3%7,423.8 6,691.77,906.65.32.9 3,725.72,315.01,640.9303.9 11.21,200.619 29.2%30.9% 1,158.01,320.5 (1)Sirton(2)28.80.8%Sirton(1)59.3428.2(2)12.211.3(3)9.171.8 管 理 層 討 論 及 分 析 (i)567.5(ii)4,601.8(iii)556.65.0% 100%21 1,2001,300 5,3115,213604.4596.4 C.2.1 企 業 管 治 及 其 他 資 料 13.51B(1) 13.51B(1) 2410 Strategic InternationalGroup Limited287,600,0001,400,000 5.242,439,8579.94%225,903,857225,953,857 121%1.00 企 業 管 治 及 其 他 資 料 1.5 *The Empire TrustThe Empire TrustThe Empire Trust *The Empire TrustThe Empire TrustThe Empire Trust**# 1% 22 Tricor Trust (Hong Kong) LimitedTricor Trust(Hong Kong) Limited 10%121%2,535,002,551 企 業 管 治 及 其 他 資 料 233,614,8079.58% 5.5 22 (1)3710,000,00022 (2)10,000,0005,000,0002,250,000 XVXV78352 (i) (2)440,000440,00041,746,0008,428,510476,774,553 (3)24,384,630440,000440,000 (4)Known Virtue International LimitedKVIKVI32,197,350 企 業 管 治 及 其 他 資 料 (ii) (L) (1)4.08% (2)0.036%0.032% XV352 336 (L)(S)(1)2,438,920,412(2)DSLCSLCSLDSL476,774,553Lambda International LimitedCSL 42.52%35.65%476,774,553(3)(4)TMF (Cayman) Ltd.476,774,55350,174,51016,486,00033,839,480TMF (Cayman) Ltd. 336 企 業 管 治 及 其 他 資 料 獨 立 審 閱 報 告 3878343434 2410 34 中 期 簡 明 綜 合 損 益 表 中 期 簡 明 綜 合 全 面 收 益 表 中 期 簡 明 綜 合 財 務 狀 況 表 中 期 簡 明 綜 合 權 益 變 動 表 中 期 簡 明 綜 合 現 金 流 量 表 中 期 簡 明 綜 合 財 務 資 料 附 註 1. Cricket Square, Hutchins Drive, P.O. Box 2681, Grand Cayman, KY1-1111, Cayman Islands 2. 2.1 34 21 2.2 171717 179 1 281212 2. 2.2 (a)12 (b)8 (c)1212 (d)12 3. (a) 10% 4. 5. 6. 7. 8. 25%Sirton Pharmaceuticals S.p.A.Sirton27.9% 8. 15% 10% 9. 10 10. 980,577,000966,893,0002,438,919,5792,448,991,145 10. 11. 11. 2,754,0002,595,000 11,112,00013,076,000 1,135,347,0001,071,168,0002,754,0002,595,00093,055,00091,668,00017 12. 999,960 14. 193,869,000208,392,000 15. 17. (a)2.30%6.54%1.4